Search Results

BioSkryb Genomics announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete DNA-informed multiomic view of the cellular ecosystem, today announced that it will introduce innovative new products and present novel research at the AGBT 2024 General Meeting on February 5-8, 2024 in Orlando, Florida.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.

BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, optimized a high-throughput workflow of BioSkryb’s ResolveDNA® Single-Cell Whole Genome Amplification technology on HP’s new D100 Single Cell Dispenser to deliver single-cell genomics at scale.

BioSkryb Genomics today announced that it will share a wide range of new research related to its recent single-cell multiomic data, single-cell whole genome sequencing and comprehensive multiomic profiling at the ASHG 2023 Annual Meeting in Washington, D.C.

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

BioSkryb Genomics today announced it has joined the NIST Genome Editing Consortium to help address the measurements and standards needed to increase confidence of utilizing genome editing technologies in research and commercial products.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment.